Irinotecan vs non‐irinotecan‐containing regimens
Tumour response · people with advanced gastric cancer
Irinotecan may leads to higher tumour response ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).
1 finding from 1 review
- OR 2.18 [1.25, 3.8]3 studies · 345 participantsLow